Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma

Critères d'exclusion

• Any prior systemic therapy for advanced HCC, • Diffuse tumor lesions, extrahepatic metastases, or vascular invasion, • Hepatic encephalopathy, • Uncontrolled ascites or pleural effusion, • Jaundice, • Severe hypotension or hemodynamic shock or need of vasoactive medications, • Decompensated heart failure New York Heart Association (NYHA) class IV, • eGFR \< 15 mL/min/1.73 m2 per MDRD (Modification of Diet in Renal Disease) formula, • Myocardial infarction within the last 6 months, • Life expectancy \<12 weeks, • Contraindications to the class of drugs under study, e.g., known hypersensitivity or allergy to calcium antagonists, • Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant, • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 3 months after the TACE treatment.